Skip to main content

Advertisement

Nobel Lectures in Cancer Immunotherapy

Nobel laureates in Physiology or Medicine James P. Allison, PhD, and Tasuku Honjo, MD, PhD, delivered their lectures "Immune Checkpoint Blockade in Cancer Therapy: New insights, opportunities, and prospects for cures" and "Serendipities of acquired immunity," respectively, in Solna, Sweden on Friday, Dec. 7, 2018. Watch their lectures and then read articles from additional leading experts in JITC's Immune Checkpoint Therapy collection.

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. 

Read more, explore our article types and sections, and submit your manuscript.

Articles

  1. Content type: Research article

      |  

    Authors: Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen and Stijn L. W. Koolen

Most accessed articles RSS

View all articles

Editor-in-Chief

Pedro Romero, Ludwig Center for Cancer Research

SITC Member Discount

SITC will provide members with a 60 percent discount on article processing charges for all JITC articles submitted and accepted in 2019.

This discount must be requested prior to submission by contacting JITCEditor@sitcancer.org. Upon receiving a waiver code from this contact, authors must select option #2 on the View Publication Charges page to enter the code in the “BioMed Central Account Number” box.

Society affiliation

Learn more about the Society for Immunotherapy of Cancer’s mission to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy at SITC Cancer Immunotherapy CONNECT.

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. View post-publication updates from the Society for Immunotherapy of Cancer on SITC CONNECT.

Latest Tweets

Advertisement

Annual Journal Metrics

Advertisement